Q-omics provides the consensus-scored FANCF profile across patient tissues and cancer cell-line models. FANCF expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, FANCF is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, FANCF RNA expression shows 20,669 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KIRP, and ACC as cancer lineages where FANCF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FANCF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FANCF survival associations across molecular data types. FANCF RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FANCF RNA expression–survival associations across cancer types. High FANCF expression shows unfavorable associations in LIHC, KICH and LGG, but favorable associations in MESO, READ and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for FANCF RNA expression.
This table summarizes FANCF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FANCF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FANCF shows higher tumor expression in KIRP, KIRC, STAD, LUAD, LIHC and HNSC. The KIRP box plot shows higher FANCF RNA expression in tumor versus normal tissue (log2 FC = +1.117, t-test p < 0.001).
This table shows molecular features associated with FANCF in patient tissues and cancer cell lines. In patient samples, FANCF shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FANCF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
